Mutagenized IL 13-based chimeric molecules
US6296843A · kind A · utility
24Cited by
4References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 3, 1998 |
| Grant date | Oct 2, 2001 |
| Priority date | — |
| Expiry date | Apr 3, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides mutagenized interleukin 13 molecules that show improved specificity for the restricted (IL4 independent) IL13 receptor and reduced cross-reactivity with the IL4/IL4 shared receptor. The mutagenized IL13 molecules include one or more mutations in a domain that interacts with the 140 kDa hIL4R.beta. or the hIL13R.alpha..sup.1 subunit. These mutagenized IL13 molecules provide effective targeting moieties in chimeric molecules (e.g. fusion proteins) that specifically deliver effector molecules (e.g. cytotoxins) to cells overexpressing IL13 receptors (e.g. cancer cells such as gliomas).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.